Travere Therapeutics, Inc. (TVTX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TVTX POWR Grades
- TVTX scores best on the Value dimension, with a Value rank ahead of 66.16% of US stocks.
- The strongest trend for TVTX is in Momentum, which has been heading up over the past 178 days.
- TVTX's current lowest rank is in the Sentiment metric (where it is better than 11.16% of US stocks).
TVTX Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for TVTX is 4.95 -- better than 90.7% of US stocks.
- TVTX's price/sales ratio is 6.47; that's higher than the P/S ratio of 83.54% of US stocks.
- With a year-over-year growth in debt of 55.54%, TRAVERE THERAPEUTICS INC's debt growth rate surpasses 82.93% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to TRAVERE THERAPEUTICS INC are CASA, ICPT, INFN, ACAD, and KOPN.
- TVTX's SEC filings can be seen here. And to visit TRAVERE THERAPEUTICS INC's official web site, go to www.retrophin.com.
TVTX Valuation Summary
- In comparison to the median Healthcare stock, TVTX's price/earnings ratio is 121.68% lower, now standing at -4.9.
- TVTX's price/earnings ratio has moved down 3.6 over the prior 124 months.
Below are key valuation metrics over time for TVTX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TVTX | 2023-03-17 | 6.5 | 32.0 | -4.9 | -6.4 |
| TVTX | 2023-03-16 | 6.5 | 32.3 | -5.0 | -6.5 |
| TVTX | 2023-03-15 | 6.5 | 32.1 | -4.9 | -6.5 |
| TVTX | 2023-03-14 | 6.7 | 32.9 | -5.1 | -6.6 |
| TVTX | 2023-03-13 | 6.6 | 32.8 | -5.1 | -6.6 |
| TVTX | 2023-03-10 | 6.3 | 31.3 | -4.8 | -6.3 |
TVTX Growth Metrics
- The 5 year revenue growth rate now stands at 32.8%.
- Its 3 year net income to common stockholders growth rate is now at -61.4%.
- The year over year net income to common stockholders growth rate now stands at 9.78%.
The table below shows TVTX's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 212.018 | -186.291 | -278.482 |
| 2022-09-30 | 213.399 | -158.528 | -264.232 |
| 2022-06-30 | 228.12 | -86.94 | -230.215 |
| 2022-03-31 | 228.57 | -43.638 | -202.195 |
| 2021-12-31 | 227.49 | -14.792 | -180.091 |
| 2021-09-30 | 221.224 | -1.785 | -250.14 |
TVTX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TVTX has a Quality Grade of C, ranking ahead of 60.91% of graded US stocks.
- TVTX's asset turnover comes in at 0.306 -- ranking 150th of 681 Pharmaceutical Products stocks.
- VTVT, FBRX, and NATR are the stocks whose asset turnover ratios are most correlated with TVTX.
The table below shows TVTX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.306 | 0.969 | -0.399 |
| 2021-06-30 | 0.291 | 0.968 | -0.396 |
| 2021-03-31 | 0.289 | 0.968 | -0.412 |
| 2020-12-31 | 0.311 | 0.969 | -0.361 |
| 2020-09-30 | 0.304 | 0.970 | -0.166 |
| 2020-06-30 | 0.303 | 0.967 | -0.194 |
TVTX Price Target
For more insight on analysts targets of TVTX, see our TVTX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $32.71 | Average Broker Recommendation | 1.25 (Strong Buy) |
TVTX Stock Price Chart Interactive Chart >
TVTX Price/Volume Stats
| Current price | $20.98 | 52-week high | $30.35 |
| Prev. close | $21.20 | 52-week low | $17.82 |
| Day low | $20.68 | Volume | 969,447 |
| Day high | $21.23 | Avg. volume | 1,546,157 |
| 50-day MA | $21.28 | Dividend yield | N/A |
| 200-day MA | $22.97 | Market Cap | 1.36B |
Travere Therapeutics, Inc. (TVTX) Company Bio
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on identifying, developing, and delivering therapies to people living with rare disease. Travere Therapeutics serves customers worldwide.
Latest TVTX News From Around the Web
Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to four new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,250 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan an |
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present a quantitative systems pharmacology (QSP) model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in classical homocystinuria (HCU), as well as real-world evidence on the prevalence and potential underdiagnosis and/or underreporting of HCU in the United States, at the 2023 Society for Inherited Metabolic Disorders (SIMD) 4 |
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional SharesSAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant, including 1,428,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase |
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsSAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.0001 per share. All of the |
Travere Therapeutics Announces Proposed Public Offering of Common StockSAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can b |
TVTX Price Returns
| 1-mo | 17.73% |
| 3-mo | 7.98% |
| 6-mo | -15.74% |
| 1-year | -16.51% |
| 3-year | 89.69% |
| 5-year | N/A |
| YTD | -0.24% |
| 2022 | -32.25% |
| 2021 | 13.89% |
| 2020 | 91.94% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...